Ira Andrew Shulman
Ira Andrew Shulman, MD
Professor of Pathology
  • :(323) 409-5266
  • :(323) 441-8193

USC School of Medicine


l964-l967   U.S. Grant High School, Van Nuys
l967-l97l BA University of California at Los Angeles
l97l-1975 Doctor of Medicine Keck School of Medicine of USC, Los Angeles, CA



Dr. Shulman is professor and Vice Chair of Pathology at the Keck School of Medicine of the University of Southern California (USC), Director of the USC Transfusion Medicine Services Group, and Director of Laboratories and Pathology at the Los Angeles County+USC Medical Center.

He  received his baccalaureate degree from UCLA (graduating summa cum laude and elected to Phi Beta Kappa), his medical degree from the USC School of Medicine (elected to AOA), and completed Pathology residency and blood banking/transfusion medicine fellowship at the Los Angeles County+USC Medical Center.

He is author or co -author of more than 100 papers, monographs, and books and book chapters, most of which deal with the clinical and laboratory practice of transfusion medicine. He has been active in the California Blood Bank Society (CBBS), the AABB, the American Society for Clinical Pathology (ASCP), the College of

American Pathologists (CAP), and the Society for the Advancement of Blood Management (SABM).

He has served as chair of several state and national organizations’ committees, including the AABB Clinical Transfusion Medicine Committee, the Transfusion Medicine Resource Committee of the CAP, and the Council on Transfusion Medicine for the ASCP and has served as president of the CBBS and on the board of directors of CBBS, AABB and SABM.

Dr. Shulman has been recognized by the CBBS for his contributions to the field of transfusion medicine as a recipient of the ‘Upton -Hemphill Award’ and the ‘Owen F. Thomas Award’, and by the AABB as a recipient of the 'Hemphill-Jordan Leadership Award'.

Research Interest

  • Pre-transfusion compatibility testing
  • Immune hemolysis
  • Transfusion transmitted infections
  • Trauma associated coagulopathy


Professional Activities:

Academic Appointments

  • Clinical Instructor, Pathology, USC School of Medicine, 1976-1979
  • Assistant Clinical Professor, Pathology, USC School of Medicine, 1979-198l
  • Assistant Professor, Pathology, USC School of Medicine, 198l-1986
  • Associate Professor, Pathology, USC School of Medicine, 1986-1994
  • Professor, Pathology, USC School of Medicine, 1994-present
  • Vice Chair, Pathology and Laboratory Medicine, 2000-present.

Specific Teaching Responsibilities

Medical Students at the University of Southern California School of Medicine

  • Lectures on Blood Groups, Blood Antibodies - l982-87, 1989-2000
  • Lectures on Autoimmune Hemolytic Anemia and Alloimmune Hemolytic Disease, 1982-87, 1989-2000
  • MDL Coordinator, Workshop on Immunohematology, l982-87,1989-2000
  • Lecture on Atherosclerosis, l982-1997
  • Lecture on Adverse Reactions to Blood Transfusions, l983-2000
  • Lecture on Blood Component Therapy, 1983-2000
  • Basic Mechanisms of Disease MDL instruction, 1975-76, l977-1983, 1995-2000
  • Cardiovascular System MDL instruction, 198l-86, 1995-1997
  • Education coordinator, Medical Student Year II, cardiovascular pathology, 1983-1991
  • Selective Elective, full day course on transfusion medicine for 3rd and 4th year USC medical students, 1987
  • Lecture to 3rd year students, preparation for clinical clerkships General Pathology for Cytology Students, USC School of Cytotechnology
  • Pathology of the cervix, 1975-1979
  • Pathology of the intestine, 1979

Blood Banking Science for Residents in Pathology, LAC-USC Medical Center

  • ABO blood group system
  • Rh blood group system
  • Blood Component Therapy
  • Blood Component Preparation
  • Immune hemolytic diseases
  • Blood Bank Rounds, general lectures on blood banking and transfusion medicine to pathology residents

USC School of Pharmacy

  • Pathology of inheritance, 1978, 1979
  • Pathology of drugs, 1979
  • Pathology of the blood, l98l
  • Pathology of malnutrition, l978-l979 UCLA Department of Pathology
  • Blood Component Therapy-Red Cell Products, 1987, 1988
  • Blood Component Therapy-Plasma Products, 1987, 1988
  • Quality Control in the Blood Bank,1987, 1988
  • Compatibility testing, 1989
  • Transfusion Transmitted Chagas Disease, 1997



  1. Chandler, R, Shulman IA, Moore R. Renal cell carcinoma presenting as a muscle mass. Clin. Orthoped and Related Diseases 1979;l45:227-229.
  2. Tindall JG, Rea TH, Shulman IA, Quismorio FP. Herpes gestationis in association with a hydatidiform mole, immunopathological studies. Arch. Dermatol. 1981;ll7:5l0-5l2.
  3. Miller C, Shulman IA, Taylor C. Demyelination with hemophagocytic lymphohistiocytosis of the CNS. Acta Neuropathol. 1981;54:l53-l55.
  4. Yoganathan AP, Reamer HH, Corcoran WH, Harrison EC, Shulman IA, Parnassus W. The Starr-Edwards aortic ball valve: Flow characteristics, thrombus formation, and tissue overgrowth. Art. Organs 1981;5(l):6-l7.
  5. Shulman IA. ABO incompatibility missed by saline immediate spin compatibility testing. Transfusion 1981;2l:469-47l.
  6. Shulman IA, Hasz L, Simpson R. Thimerosal dependent cell agglutination: a newly described blood bank problem. Transfusion 1982;22:24l-243.
  7. Reynard M, Shulman IA, Azen S, Minckler D. Histocompatibility antigens in sympathetic ophthalmia. Am J. Ophthalmol. 1983;95:2l6-22l.
  8. Branch D, Gallagher M, Shulman IA, Mison A, Hian A, Petz L. Reticuloendothelial cell function in alpha-methyldopa induced hemolytic anemia. Vox Sang. 1983;45:278-287.
  9. Shulman IA, Saxena S, Nelson JM, Furmanski M. Neonatal exchange transfusions complicated by transfusion malaria. Pediatrics 1984;73:330-332.
  10. Branch D, Shulman IA, Sy Siok Hian AL, Petz LD. Two distinct categories of warm antibody reactivity with age fractionated red cells. Blood 1984;63:l77-l80.
  11. Wheeler D, Nelson JM, Shulman IA, Okamoto M. A new subgroup of group B blood. Blood 1984;63:7ll-7l3.
  12. Shulman IA, Nelson JM, Saxena S, Thompson J, Kent D, Okamoto M, Nakayama R. The routine use of an abbreviated crossmatch. Am.J. Clin. Pathol. 1984;82:l78-l8l.
  13. Shulman IA, Simpson R, Farmer C, Lam H-T. Thimerosal dependent agglutination complicating the serologic evaluation for unexpected antibodies. Transfusion 1984;24:365-367.
  14. Shulman IA, Nelson JM, Lam H-T, Meyer E, Okamoto M. DTT modified RBCs: a new approach to the identification of antibodies directed at high frequency Kell and Cartwright antigens. Lab. Med. 1984;l5:607-608.
  15. Shulman IA, Branch RB, Nelson JM, Thompson JC, Saxena S, Petz LD. Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA 1985;253:l746-l748.
  16. Shulman IA, Nelson JM, Kent DR, Jacobs V, Nakayama R, Malone SA. Experience with a cost effective crossmatch protocol. JAMA 1985;254:93-95.
  17. Shulman IA, Nelson JM, Okamoto M, Malone SA. The dependence of anti-JKa detection on screening cell zygosity. Lab. Med. 1985;l6:602-604.
  18. Bertram JH, Grunberg SM, Shulman IA, Apuzzo ML, et al. The staphylococcal protein A column; correlation of mitogenicity of perfused plasma with clinical response. Cancer Res. 1986;45:4486-4494.
  19. O'Neill P, Shulman IA, Simpson R, Halima D, Garratty G. Two examples of low ionic strength-dependent autoagglutinins with anti-Pr specificity. Vox Sang 1986;50:l07-lll.
  20. Jamin D, Demers J, Shulman IA, Lam H-T, Momparier R. An explanation for non-immunologic adsorption of proteins onto red blood cells; Schiff's base reactions. Blood 1986;67:993-996.
  21. Shulman IA, Kiyabu M, Nelson JM, Okamoto M, Lam H-T, Meyer E. The use of pooled antibody screening red cells during pretransfusion compatibility testing. Lab. Med. 1986;l7:407-408.
  22. Shulman IA, Nelson JM. The pros and cons of the abbreviated crossmatch. J. Med. Technol. 1986;7:417 419.
  23. Shulman IA, Meyer E, Nakano F, Seymour M, Kent D, Ching J. Blood bank serologic problems caused by human thrombin. J. Med. Technol. 1986;8:455-456.
  24. Perez D, Cohen DW, Shulman IA, Branch DR. Rhesus Du incompatibility in a newborn without hemolytic disease: a possible role for the mononuclear phagocyte system in the benign clinical course. Vox Sang 1986;51:341-343.
  25. Thompson J, Shulman I, Nelson J, Okamoto M. Life saving incompatible blood transfusion. Lab. Med. 1987;18:385 387.
  26. Shulman IA, Saxena S, Nelson JM. The impact of alanine aminotransferase testing on Hispanic blood donations. Arch of Pathol & Lab Med 1987;111:988-989.
  27. Zeidler A, Vadheim P, Shaw S, Langbaum M, Rotter J, Shulman I, Costin G, Riley W, Maclaren N. Genetic predisposition to insulin dependent diabetes mellitus in Mexican descendents. Border Health 1987;3(1):2-7.
  28. Reid ME, Vengelan-Tyler V, Shulman I, Reynolds M. Immunochemical Specificity of Autoanti-Gerbich from two patients with autoimmune haemolytic amaemia and concomittant alteration in the red cell membrane sialoglycoprotein beta. British Journal of Hematology 1988;69:61-66.
  29. Jamin D, Shulman I, Lam H-T, Scott A, Shields M, Cohen J, Gill P, Levine A. Suramin: Production of a positive direct antiglobulin test. Archieves of Pathology and Lab Medicine 1988;112:898-900.
  30. Sniecinski I, Margolin K, Shulman I, Oien L, Meyer E, Branch D. High titer, high thermal amplitude cold autoagglutinin not associated with hemolytic anemia. Vox Sanguinis 1988;55:26-29.
  31. Saxena S, Endohl GE, Shulman IA. Use of a table-top analyzer for pre-donation screening for alanine aminotransferase, a cost effective approach? AJCP 1988;90:296-299.
  32. Silver H, Shulman IA, Smith DM, Umlas, J, Wallace ME [Council on Transfusion Medicine of the ASCP Commission on Continuing Education]. The expanded role of the pathologist in transfusion medicine. Laboratory Medicine 1988;19:672-673.
  33. Bertram JH, Snyder HW, Gill PS, Shulman IA, Henry DH, Jenkins D, Kiprov DD. Protein A immunoadsorption therapy in HIV-related immune thrombocytopenia: a priliminary report. Artificial Organs 1988;12:484-490.
  34. Shulman IA, Yaowasiriwatt M, Saxena S, Nelson JM. Influence of reagent red cell zygosity on anti-fya detection. Lab Medicine 1989;20:37-39.
  35. Meyer EA, Shulman IA. The sensitivity and specificity of the immediate spin crossmatch. Transfusion 1989;29:99-102.
  36. Shulman IA, Morales J, Nelson JM, Saxena S. Emergency Transfusion Protocols. Laboratory Medicine 1989;20:166 168.
  37. Strautz RL, Nelson JM, Meyer EA, Shulman IA. Compatibility of ADSOL stored red cells with intravenous solutions. American Journal of Emergency Medicine 1989;7:162-164.
  38. Saxena S, Shulman IA, Wong E, Shaw T. Higher serum alanine aminotransferase levels among Hispanics in a reference population. Laboratory Medicine 1989;20:264 266.
  39. Shulman IA, Kent D. Is it safe to eliminate the major crossmatch for selected patients? Archives of Pathology and Laboratory Medicine 1989;113:270-272.
  40. Saxena S, Korula J, Shulman IA. A review of donor ALT testing: Implications for the blood donor and practitioner. Archives of Path and Lab Medicine 1989;113:767-771.
  41. hulman I. Adverse reactions to blood transfusion. Texas Medicine 1989;85:35-42.
  42. Carmel R, Shulman IA, Blood transfusion in medically treatable chronic anemia: Pernicious anemia as a model for transfusion overuse. Archives of Path and Lab Med 1989;113:995-997.
  43. Vadheim CM, Zeidler A, Rotter JI, Langbaum M, Shulman IA, et al. Different HLA haplotypes in type 1 diabetes in Mexican-Americans. Diabetes Care 1989;12:497-500.
  44. Shulman IA, Nelson JM, Nakayama R. When should antibody screening tests be done for recently transfused patients? Transfusion 1990;30:39-41.
  45. Shulman IA. The risk of an overt hemolytic transfusion reaction following the use of an immediate spin (IS) crossmatch. Archives of Path and Lab Med 1990;114:412 414.
  46. Shulman IA, Arndt P, McGehee W, Garratty G. Cefotaxime induced immune hemolytic anemia due to antibodies reacting in vitro by more than one mechanism. Transfusion 1990;30:263-266.
  47. Saxena S, Shulman IA. The impact of screening a heterogeneous donor population for alanine aminotransferase and hepatitis B core antibody (Experience at a large Southern California hospital). AJCP 1990;93:533-537.
  48. Saxena S, Odono V, Francis RB Jr, Endahl GL, Shulman IA. Can storage of thawed cryoprecipitate be extended to more than six hours. Am J Clin Pathol. 1990 Aug;94(2):203-6.
  49. Saxena S, Odono V, Uba J, Nelson JM, Lewis W, Shulman IA. The risk of bacterial growth in units of blood that have warmed to over 10C. AJCP 1990;94:80-83.
  50. Shulman IA, Vengelen-Tyler V, Thompson JC, Nelson JM, Chen DCT. Autoanti-Ge associated with severe autoimmune hemolytic anemia. Vox Sanguinis 1990;59:232-234.
  51. Tschirhart R, Kunkel L, Shulman IA. Immune hemolytic anemia associated with biclonal cold autoagglutinins. Vox Sanguinis 1990;59:222-226.
  52. Shulman IA, Kent D. Unit placement errors, a potential risk factor for ABO and Rh incompatible blood transfusions. Laboratory Medicine 1991;22:194-196.
  53. Saxena S, Odono V, Francis R, Shulman IA. Is the storage of thawed cryoprecipitated AHF better at 1-6C than at room temperature for factor VIII content? Archives of Pathol and Lab Med. 1991;115:343-345.
  54. Shulman IA, Nakayama R, Calderon C. The sensitivity of antibody detection testing using pooled vs unpooled reagent RBCs. Immunohematology 1991;7:16-19.
  55. Shulman IA, Calderon C. The effect of delayed centrifugation or reading on the detection of ABO incompatibility by the immediate spin crossmatch. Transfusion 1991;31:197-200.
  56. Gaciong Z, Alexiewicz JM, Linker-Israeli M, Shulman IA, Pitts TO, Massry SG. Inhibition of immunoglobulin production by parathyroid hormone. Implications in chronic renal failure. Kidney International 1991;40:96 106.
  57. Shulman IA. Parasitic infections, an uncommon risk of blood transfusion in the United States. Transfusion 1991;31:479-480.
  58. Shulman IA, Appleman MD. Transmission of parasitic and other non-viral diseases through blood transfusion in the U.S. Critical Reviews in Clinical Laboratory Sciences 1991;28:447-459.
  59. Kerndt PR, Waskin H, Kirchoff LV, Steurer F, Waterman S, Nelson JM, Gellert G, and Shulman IA. Prevalence of antibody to Trypanosoma Cruzi among blood donors in Los Angeles, California. Transfusion 1991;31:814-818.
  60. Shulman IA. Transfusion Medicine 1980-1990. AJCP 1991;96(Suppl 1):S25-S32.
  61. Shulman IA. Safety in transfusion practices; red cell compatibility testing issues. Clinics in Laboratory Medicine 1992:12:(3)1-16.
  62. Sakai LM, Baker LA, Jacklin CN, Shulman IA. Sex steroids at birth: Genetic and environmental variation and covariation. Developmental Psychobiology 1992;24:559-570.
  63. Appleman MD, Shulman IA, Saxena S, Kirckhoff LV. Use of a questionnaire to detect blood donors at high risk of infection with T. cruzi. Transfusion 1993;33:61-64.
  64. Saxena S, Rabinowitz A, Johnson C, Shulman IA. Iron deficiency anemia: a medically treatable chronic anemia as a model for transfusion overuse. American Journal of Medicine 1993;94:120-124.
  65. Shulman IA, Nakayama R. Experience with the routine use of soluble Lewis antigens in the identification of Lewis antibodies. Transfusion 1993;33:37-41.
  66. Yamada AH, Lieskovsky G, Skinner DG, Shulman IA, Groshen S, Su-Chiu C. Impact of autologous blood transfusions on patients undergoing radical prostatectomy utilizing hypotensive anesthesia. J Urology 1993;149:73-76.
  67. Carter-Pokras OD, Najjar MF, Billhymer BF, Shulman IA. Alanine aminotransferase (ALT) levels in Hispanics. Ethnicity and Disease 1993;176-180.
  68. Garratty G, Arndt P, Prince HE, Shulman IA. The effect of methyldopa and procainamide on suppressor cell activity in relation to red cell autoantibody production. British Journal of Medicine 1993;84:310 315.
  69. Saxena S, Shulman IA, Johnson C. Effect of blood transfusion on serum iron and transferrin saturation. Archives of Path and Lab Med 1993;117:622-624.
  70. Saxena S, Weiner JM, Rabinowitz A, Fridey J, Shulman IA, Carmel R. Transfusion practice in medical patients. Arch Internal Med 1993;153:2575-2580.
  71. Shulman IA, Lohr K, Derdiarian A, Picukaric JM. Monitoring transfusionist practices: a strategy for improving transfusion safety. Transfusion 1994;34:11 15.
  72. Shulman IA. Parasitic infections and their impact on blood donor selection and testing. Arch Path Lab Med 1994;118;366-370.
  73. Pestaner J, Shulman IA. Is it safe to omit the 37C reading from pretransfusion compatibility testing? AJCP 1994:101;361-364.
  74. Shulman IA, Calderon C, Nelson JM, Nakayama R. The routine use of Rh negative reagent red cells for the identification of anti-D and the detection of non-D red cell antibodies. Transfusion 1994:34:666-670.
  75. Saxena S, Korula J, Fong TL, Shulman IA. Are Gender-Specific ALT Cutoff Values Necessary? Laboratory Medicine, 1995;26:p682-686.
  76. Lam HT, Schweitzer SO, Petz L, Myhre BA, Shulman IA, Kanter MH, Worthen B, Sun GW. Are Retrospective Peer-review Transfusion Monitoring System Effective in Reducing Red Blood Cell Utilization? Archives of Pathology and Laboratory Medicine 1996;120:810-816.
  77. Shulman IA, Zuckerman M, et al. Use of a novel clot accelerating reagent in stat blood bank testing. Laboratory Hematology 1996;2:35-39.
  78. Calderon C, Nelson JM, Luey J, Shulman IA, South S. Case in Point. Advance for Medical Laboratory Professionals 1996; 8(20): 2.
  79. Laine EP, Nelson JM, George FW, Shulman, IA. Hyperkalemia After Massive Blood Transfusion. Laboratory Medicine 1997;28:305-308.
  80. Petz LD, Calhoun L, Shulman IA, Johnson C, Herron RM. The Sickle Cell Hemolytic Transfusion Reaction Syndrome. Transfusion 1997;382-392..
  81. Shulman IA, Jones FS. Practical Aspects of the Self-Assessment of the Issue and Administration of Blood, A Review of Two Hospitals’ Experiences”, AJCP 1997; 107(S):S17-22.
  82. Bennett DR, Shulman IA. Practical Issues When Confronting the Patient Who Refuses Blood Transfusion Therapy. AJCP 1997;107(S)S23-S27.
  83. Lam HT, Schweitzer SO, Petz L, Kanter MH, Bernstein DA, Brauer S, Pascual D, Myhre BA, Shulman IA, Sun GW. Effectiveness of a prospective self audit transfusion-monitoring system. Transfusion 1997;37:577-584.
  84. Shulman IA, Appleman MD, Saxena S, Hiti AL, Kirchkoff LV. Specific antibodies to Trypanosoma cruzi among blood donors in Los Angeles, California. Transfusion 1997:37;727-731.
  85. Zeger G, Williams CT, Shulman IA. Single donor platelets: Can we afford to use them? Can we afford NOT to use them? Transfus Sci 1997;18:585-588.
  86. Shulman IA. The "virtual" transfusion service laboratory. Transfusion 1997;37:883-885.
  87. Simon T, Alverson D, AuBuchon J, Cooper ES, DeChristopher P, Gleen GC, Gould SA, Harrison CR, Milam JD, Moise KJ, Rodwig FR, Sherman LA, Shulman IA, Stehling L. Practice Parameter for the use of Red Blood Cells. Archives of Pathology and Lab Med 1998;122:130-138.
  88. Maffei LM, Johnson ST, Shulman IA, Steiner EA. Survey on pretransfusion testing. Transfusion 1998;38:343-349.
  89. Sherwood T, Shulman I, Pierre R. Satellitosis of erythrocytes about mature neutrophils. Laboratory Hematology 1998;4:207-210.
  90. Shulman IA. Intervention strategies to reduce the risk of transfusion-transmitted Trypanosoma cruzi infection in the United States. Transfusion Medicine Reviews 1999;13 (3); 227-234.
  91. Shulman IA, Saxena S, Ramer L. Assessing blood administering practices. Arch Pathol Lab Med. 1999;123(7):595-8.
  92. Sazama K, DeChristopher P, Dodd R, Harrison C, Shulman IA, Cooper ES, Laborka RJ, Oberman HA, Zahn CM, Greenburg AG, Stehling L, Lauenstein KJ, Price TH, Williams LK. Practice Parameter for the Recognition, Management, and Prevention of Adverse Consequences of Blood Transfusion. Arch Pathol Lab Med 2000;124(1):61-70
  93. Saxena S, Wehrli G, Makarewicz K, Sartorelli J, and Shulman I. Monitoring for under-utilization of red cell products and platelets. Transfusion 2001; 41: 587-590.
  94. Shulman IA, Downes KA, Sazama K, Maffei LM. Pretransfusion compatibility testing for red blood cell administration. Curr Opin Hematol. 2001;8(6):397-404.
  95. Sacher RA, Kickler TS, Schiffer CA, Sherman LA, Bracey AW, Shulman IA. Management of Patients Refractory to Platelet Transfusion. Arch of Path and Lab Med 2003;127: 409-414.
  96. Davoren A, Curtis BR, Shulman IA, Mohrbacher AF, Bux J, Kwiatkowska BJ, McFarland JG, Aster RH. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion 2003;43(5):641-5.
  97. Saxena S, Shulman IA, Pachciarz J, Downey N, Figueroa PI. Retrospective targeted HCV lookback using centralized contracted notification service.Transfusion. 2003 Jun;43(6):799-805.
  98.  Saxena S, Shulman IA. Resurgence of the blood utilization committee. Transfusion. 2003 Aug;43(8):998-1006.
  99. Dzik WH, Corwin H, Goodnough LT, Higgins M, Kaplan H, Murphy M, Ness P, Shulman I, Yomtovian R. Patient safety and blood transfusion: New Solutions. Transfusion Medicine Reviews 2003; 17 (No 3):169-180.
  100.  Saxena S, Belzberg H, Chogyoji M, Wilcox S, Shulman IA. Reducing phlebotomy losses by streamling laboratory test ordering in a surgical intensive care unit. Laboratory Medicine 2003;34:728-732.
  101. Saxena S, Ramer L, Shulman IA. A comprehensive assessment program to improve blood administering practices using the FOCUS-PDCA model. Transfusion 2004;44:1350-1356.
  102. Shulman IA. College of American Pathologists Laboratory Accreditation Checklist Item TRM.44955. Phase I Requirement on Bacterial Detection in Platelets. Arch Pathol Lab Med 2004;128:958-963.
  103. Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: A survey of 1182 North American Laboratories. Arch of Pathol Lab Medicine 2005;129:190-193.
  104. Shander A, Aledort L, Broder M, Busch M, Custer B, Fergusson D, Goodnough L, Hendler R, Hoffman A, Klein H, Louie J, Page P, Sazama K, Shulman IA, Spence R, Sullivan M, Thurer R. The cost of blood: multidisciplinary consensus conference for a standard methodology. Transfusion Medicine Reviews;19:66-78.
  105. Shulman IA, Maffei L, Downes K. North American Pre-Transfusion Testing Practices, 2001-2004: Results from the College of American Pathologists (CAP) Inter-laboratory Comparison Program Survey Data, 2001-2004. Arch Pathol Lab Med. 2005 Aug;129(8):984-9.
  106. Shulman IA, Osby M. Storage and transfusion of infected autologous blood or components: a survey of North American laboratories. Arch Pathol Lab Med. 2005 Aug;129(8):981-3
  107. Saxena S, Kempf R, Wilcox S, Shulman IA, Wong L, Cunningham G, Vega E, Hall S. Critical Laboratory Value Notification: A Failure Mode Effects and Criticality Analysis. Journal on Quality and Patient Safety 2005:31 (9):495-506.
  108. Shulman IA, Saxena S. The transfusion services committee – Responsibilities and Response to adverse transfusion events. Hematology (Am Soc Hematol Educ Program). 2005: 483-90
  109. Beale E, Zhu J, Chan L, Shulman IA, Harwood R, Demetriades D. Blood transfusion in critically injured patients: a prospective study. Injury 2006;37(5):455-65
  110. Shulman, IA. Prophylactic phenotype matching of donors for the transfusion of non-alloimmunized patients with sickle cell disease. Immunohematology 2006;22:101-102.
  111. Saxena S, Nelson JM, Osby M, Shah M, Kempf R, Shulman IA. Ensuring timely completion of type and screen testing and the verification of ABO/Rh status for elective surgical patients. Arch Pathol Lab Med. 2007;131:576-581.
  112. Murphy MF, Casbard AC, Ballard S, Shulman IA, Heddle N, Aubuchon JP, Wendel S, Thomson A, Hervig T, Downes K, Carey PM, Dzik WH on behalf of the BEST Research Collaborative. Prevention of bedside errors in transfusion medicine (PROBE-TM) study: a cluster-randomized, matched- paired-clinical area trial of a simple intervention to reduce errors in the pre-transfusion bedside check. Transfusion 2007;47:771-780.
  113. Osby M, Nelson JM, Saxena S, Shulman IA. Safe Handling and Administration of Blood Components: Review of Practical Concepts. Arch of Path and Lab Med 2007;131:690-694
  114. Fung M, Downes K, Shulman IA. Transfusion of platelets containing ABO-incompatible plasma: A Survey of 3,156 North American laboratories. Arch of Path and Lab Med 2007;131:909-916.
  115. Kopko P, Silva M, Shulman I, Kleinman S. AABB survey of transfusion-related acute lung injury policies and practices in the United States. Transfusion. 2007;47:1679-85.
  116. Plurad D, Belzberg H, Shulman I, Green D, Salim A, Inaba K, Rhee P, Demetriades D. Leukoreduction is associated with a decreased incidence of late onset acute respiratory distress syndrome after injury. The American Surgeon 2008;74:117-123.
  117. Teixeira PG, Oncel D, Demetriades D, Inaba K, Shulman I, Green D, Plurad D, Rhee P. Blood transfusions in trauma: six-year analysis of the transfusion practices at a Level I trauma center. Am Surg. 2008 Oct;74(10):953-7.
  118. Inaba K, Teixeira PG, Shulman I, Nelson J, Lee J, Salim A, Brown C, Demetriades D, Rhee P.The impact of uncross-matched blood transfusion on the need for massive transfusion and mortality: analysis of 5,166 uncross-matched units. J Trauma 2008 Dec;65(6):1222-6
  119. Hadjizacharia P, Green D, Plurad D, Chan L, Inaba K, Shulman I, Demetriades D. Methamphetamines in Trauma: Effect on Injury Patterns and Outcome. J Trauma 2009;66:895– 898.
  120. Teixeira P, Inaba K, Shulman I, Salim A, Demetriades D, Brown C. Browder T, Green D, and Rhee P, Impact of Plasma Transfusion in Massively Transfused Trauma Patients. J Trauma 2009;66:693– 697
  121. Cremer ML, Alonzo TA, Alspach AE, Shulman IA, Cernosek S, Felix JC. Diagnostic reproducibility of CIN 3 and atrophy in menopausal women on H&E, Ki-67 and P16 stained slides. Journal of the Lower Genital Tract. 2010 Apr;14(2):108-12.
  122. Inaba K, Lustenberger T, Rhee P, Holcomb JB, Blackbourne LH, Shulman I, Nelson J, Talving P, Demetriades D. The Impact of Platelet Transfusion in Massively Transfused Trauma Patients. J Am Coll Surg. 2010;211:573-579.
  123. Inaba K, Branco BC, Rhee P, Holcomb JB, Blackbourne LH, Shulman I, Nelson J, Demetriades D. Impact of ABO-identical vs ABO-compatible non-identical plasma transfusion in trauma patients. Arch Surg. 2010 Sep;145(9):906.
  124. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Teixeira PG, Shulman I, Nelson J, Demetriades D. Impact of plasma transfusion in trauma patients who do not require massive transfusion. J Am Coll Surg. 2010 Jun;210(6):957-65.
  125. Jacobs MR, Smith D, Heaton WA, Zantek ND, Good CE and the PGD Study Group (a group of 15 authors, including Shulman IA). Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion. 2011 Dec;51(12):2573-82.
  126. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Spinella PC, Shulman IA, Nelson J, Demetriades D. The Impact of the Duration of Platelet Storage in Critically Ill Trauma Patients. Journal of Journal of Trauma, Injury, Infection and Critical Care. 2011 Dec;71(6):1766-73; discussion 1773-4.
  127. Branco BC, Inaba K, Doughty R, Brooks J, Barmparas G, Shulman I, Nelson J, Demetrios D. The Increasing Burden of Phlebotomy in the Development of Anemia and Need for Blood Transfusion Among Trauma Patient. Injury 2012 Jan;43(1):78-83.
  128. Downes KA, Shulman IA. Pretransfusion Testing Practices in North America, 2005 to 2010. Archives of Pathology & Laboratory Medicine: March 2012, Vol. 136, No. 3, pp. 294-300
  129. Ives C, Inaba K, Branco B, Okoye O, Schochl H, Talving P, Lam L, Shulman I, Nelson J, Demetriades D. Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg 2012;215:496–502.
  130. Nosanov L, Inaba K, Okoye O, Resnick S, Upperman J, Shulman I, Rhee P, Demetriades D. The impact of blood product ratios in massively transfused pediatric trauma patients. Am J Surg. 2013 Nov;206(5):655-660.
  131. Inaba K, Karamanos E, Lustenberger T, Schochl H, Shulman I, Nelson J, Rhee P, Talving P, Lam L, Demetriades D. The impact of fibrinogen levels on outcomes after acute injury in patients requiring a massive transfusion. J Am Coll Surg. 2013 Feb;216(2):290-297.
  132. Kim MY, Chaudhary P, Shulman IA, Pullarkat V. Major Non-ABO incompatibility due to anti-Jka antibody in a patient prior to allogeneic hematopoietic stem cell transplantation. Immunohematology. 2013;29:11-14.
  133. Shander A, Michelson EA, Sarani B, Flaherty ML, Shulman IA. Use of Plasma in the Management of Central Nervous System Bleeding: Evidence-based Consensus Recommendations. Advances in Therapy Journal 2014 Jan;31(1):66-69
  134. Branco BC, Inaba K, Ives C, Okoye O, Shulman I, David JS, Schöchl H, Rhee P, Demetriades D. Thromboelastogram Evaluation of the Impact of Hypercoagulability in Trauma Patients. Shock 2014. Mar;41(3):200-207
  135. Baraniuk S, Tilley BC, del Junco DJ, Fox EE, van Belle G, Wade CE, Podbielski JM, Beeler AM, Hess JR, Bulger EM, Schreiber MA, Inaba K, Fabian TC, Kerby JD, Cohen MJ, Miller CN, Rizoli S, Scalea TM, O'Keeffe T, Brasel KJ, Cotton BA, Muskat P, Holcomb JB; PROPPR Study Group (a group of 146 authors, including Shulman IA). Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: Design, rationale and implementation. Injury 2014 Sep;45(9):1287-95.
  136. Sand D, She R, Shulman IA, Chen DS, Schur M, Hsu HY. Microbial Keratitis in Los Angeles: The Doheny Eye Institute and the Los Angeles County Hospital Experience. Ophthalmology 2015 May;122(5):918-24.
  137. Novak DJ, Bai Y, Cooke RK, Marques MB, Fontaine MJ, Gottschall JL, Carey PM, Scanlan RM, Fiebig EW, Shulman IA, Nelson JM, Flax S, Duncan V, Daniel-Johnson JA, Callum JL, Holcomb JB, Fox EE, Baraniuk S, Tilley BC, Schreiber MA, Inaba K, Rizoli S, Podbielski J, Cotton BA, and Hess JR on behalf of the PROPPR Study Group. Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: the experience of the PROPPR trial centers. Transfusion 2015 Jun;55(6):1331-9
  138. Haltmeier T, Inaba K, Effron Z, Dollbaum R, Shulman I, Benjamin E, Lam L, Demetriades D. Candida score as a predictor of worse outcomes and mortality in severely injured trauma patients with positive candida cultures. Am Surg. 2015 Oct;81(10):1067-73.
  139. King JR, Zeger GD, Plaza N, Lee RH, Shulman IA. Fetal-Maternal hemorrhage detected by sudden disappearance of Rh Immune Globulin related anti-D. Obstet Gynecol. 2015 Dec;126(6):1301-2.
  140. Bui E, Inaba K, Ebadat A, Karamanos E, ByerlyS, Okoye O, Shulman I, Rhee P, Demetriades D. The impact of increased plasma ratios in massively transfused trauma patients: a prospective analysis. Eur J Trauma Emerg Surg. 2015 Sep 11.
  141. Van Winden K, Poisson J, Lee RH, Agarwal R, Ouzounian JG, Shulman IA. Non-specific red-cell reactivity in an obstetric population. J Matern Fetal Neonatal Med. 2015 Nov 23:1-4.
  142. Da B, Shulman I, Lane C, Buxbaum J. Origin, Presentation, and Clinical Course of Non Pancreatic Hyperlipasemia. Pancreas 2015; in press.


clinical-laboratory-medicine-flyer Flyer